List of Studies ( Metabolite:2-Methyl-tridecanedioic acid)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004153 | AN006895 | Multi-omics Study of Small Intestine Adaptation After Total Colectomy in a Rat model | Feces | Rat | Shanghai Jiao Tong University | LC-MS | |
| ST003144 | AN005160 | On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002792 | AN004543 | Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002698 | AN004373 | Systemic host inflammation induces stage-specific transcriptomic modification and slower maturation in malaria parasites | Infected Red Blood Cells | Plasmodium berghei | Malaria | Peter Doherty Institute for Infection and Immunity | LC-MS |
| ST002094 | AN003420 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | LC-MS |
| ST002094 | AN003421 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | LC-MS |
| ST002094 | AN003422 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | LC-MS |
| ST001788 | AN002900 | β-Adrenergic regulation of metabolism in macrophages (part-IV) | Macrophages | Human | Monash University | LC-MS | |
| ST000422 | AN000667 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | LC-MS |
| ST000422 | AN000668 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | LC-MS |
| ST000422 | AN000670 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | LC-MS |
| ST000421 | AN000663 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | LC-MS |
| ST000421 | AN000664 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | LC-MS |
| ST000310 | AN000490 | TC and B6 untreated plasma in lupus-prone mice lipidomics (part-II) | Blood | Mouse | Lupus | University of Florida | LC-MS |
| ST000310 | AN000492 | TC and B6 untreated plasma in lupus-prone mice lipidomics (part-II) | Blood | Mouse | Lupus | University of Florida | LC-MS |
| ST000046 | AN000078 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | LC-MS |
| ST000046 | AN000079 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | LC-MS |
| ST000045 | AN000075 | Plasma metabolomics: Comparison of non-diabetic controls with T1D patients | Blood | Human | Mayo Clinic | LC-MS |
